Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 131-138

  Ishihara, Yasuhiro ^a   Ohmori, Koji ^a   Mizukawa, Mizuki ^a   Ul Hasan, Arif ^a   Noma, Takahisa ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Adipocyte; Adiponectin; Insulin resistance; Lipogenesis; Lipolysis; Statin

Indexed keywords

ADIPONECTIN; GLUCOSE TRANSPORTER 4; HORMONE SENSITIVE LIPASE; INSULIN; PITAVASTATIN; PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; COULTER COUNTER; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HYPERPHAGIA; HYPERTROPHY; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; UPREGULATION; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; CELL SIZE; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; GLUCOSE TRANSPORTER TYPE 4; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY; INSULIN; INSULIN RESISTANCE; LIPOGENESIS; LIPOPROTEIN LIPASE; MICE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINOLINES; TIME FACTORS; TRIGLYCERIDES;

EID: 77956226709     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.019     Document Type: Article

References (29)

1. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
2. Yu Y., Ohmori K., Chen Y., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004, 44:904-913.
3. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-2192.
4. Ishikawa M., Namiki A., Kubota T., et al. Effect of pravastatin and atorvastatin on glucose metabolism in non-diabetic patients with hypercholesterolemia. Intern Med 2006, 45:51-55.
5. Chen Y., Ohmori K., Mizukawa M., et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007, 71:144-152.
6. Sugiyama S., Fukushima H., Kugiyama K., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-51.
7. Takagi T., Matsuda M., Abe M., et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008, 196:114-121.
8. Takaguri A., Satoh K., Itagaki M., Tokumitsu Y., Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008, 107:80-89.
9. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
10. Kadowaki T., Hara K., Yamauchi T., Terauchi Y., Tobe K., Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 2003, 228:1111-1117.
11. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
12. Okamoto T., Okamoto Y., Kihara S., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
13. Aleci M.C., Juhan-Vague I. PAI-1 and the metabolic syndrome. Links, causes, and consequences. Atheroscler Thromb Vasc Biol 2006, 26:2200-2207.
14. Mäuser W., Perwitz N., Meier B., Fasshauer M., Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007, 564:37-46.
15. Laumen H., Skurk T., Hauner H. The HCG-CoA reductase inhibitor rosuvastatin inhibits Plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis 2008, 196:565-573.
16. Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS). J Am Coll Cardiol 2009, 54:293-302.
17. Nomura S., Shouzu A., Omoto S., et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res 2008, 122:39-45.
18. Nicholson A.C., Hajjar D.P., Zhou X., He W., Gotto A.M., Han J. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression. Br J Pharmacol 2007, 151:807-815.
19. Lv H., Sun J.G., Wang G.J., et al. Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteer. Clin Chim Acta 2007, 386:25-30.
20. Ferrari M., Fornasiero M.C., Isetta A.M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 1990, 131:165-172.
21. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385:165-168.
22. Sakai T., Sakaue H., Nakamura T., et al. Skp2 controls adipocyte proliferation during the development of obesity. J Biol Chem 2007, 282:2038-2046.
23. Hirsch J., Gallian E. Methods for the determination of adipose cell size in man and animals. J Lipid Res 1968, 9:110-119.
24. Gonzales A.M., Orland R.A. Role of adipocyte-derived lipoprotein lipase in adipocyte hypertrophy. Nutr Metab (Lond) 2007, 4:22.
25. Sakaeda T., Fujino H., Komoto C., et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharmaceut Res 2006, 23:506-512.
26. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
27. Maebuchi M., Machidori M., Urada R., et al. Low resistin level in adipose tissue and serum in high-fat fed mice and genetically obese mice: development of an ELISA system for quantification of resistin. Arch Biochem Biophys 2003, 416:164-170.
28. Yagi S., Aihara K., Ikeda Y., et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 2008, 102:68-76.
29. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.